NEWS | GLP-1: Miracle Drug or Hype? Exploring Recent Advances in GLP-1 Medicine

Introduction

You’ve likely heard of a drug known as GLP-1, as it has become one of the most widely publicized topics in science in 2025. It is everywhere from social media to television commercials, with people touting it as a “miracle drug” because of its ability to be an effective treatment for many widespread health problems that large portions of society are facing, such as obesity and type 2 diabetes. In this article, we will look at the science behind this groundbreaking medicine, explore its uses, how it became so popular, and the future of GLP-1 medicine.

GLP-1 background

While often referred to as GLP-1, the true name for the primary ingredient in these drugs is GLP-1 receptor agonists (GLP-1RA), a peptide hormone that mimics the effects of the incretin hormone GLP-1, which is released by the gut after food consumption. Research into GLP-1RA began long before widespread knowledge of its existence among the general public. In the early 1970s, new approaches to predicting amino acid sequences of proteins by decoding nucleotide sequences of cloned recombinant DNA led to the discovery of GLP-1 and GLP-2. While drugs like Ozempic and Wegovy only recently exploded in popularity, GLP-1RA-based drugs were approved by the FDA to treat diabetes in the mid-2000s, after numerous clinical trials and successful studies. Since then, expanded research into the potential uses for GLP-1RA-based drugs has led to treatments being approved for much more than just diabetes, which is what the drug was originally designed for.

The history and background of GLP-1 Drug Development

GLP-1RA Mechanism of Action

The primary function of GLP-RA-based drugs is to mimic the actions of the GLP-1 peptide by binding to GLP-1 receptors on the surface of pancreatic beta cells, leading to a variety of events occurring: They slow gastric emptying, inhibit the release of glucagon, and stimulate insulin production, therefore reducing hyperglycemia, which occurs when there is too much glucose in the bloodstream. These actions maximize nutrient absorption while limiting weight gain. They also increase satiety and, therefore, body weight, making them an effective obesity treatment.

Uses for GLP-1RA and how it exploded in popularity

As previously mentioned, GLP-1RA-based drugs were originally intended as a treatment for diabetes, but since the debut of GLP-1RA drugs in the pharmaceutical landscape, multiple new uses for them have emerged. The primary reason for this is due to the side effects reported by users of the drug for its intended purpose: diabetes treatment. The most common side effect was weight loss in a relatively short period, and research into other effects that GLP-1RA has on the body began after scientists noticed that the drugs would often do more than their intended purpose. After it was confirmed that GLP-1RA played a role in weight loss, new drugs such as Ozempic and Wegovy (semaglutide) were developed to treat obesity, and this is mainly responsible for the large increase in GLP-1RA drug users. According to the NIH, more than 2 in 5 adults suffer from obesity in the United States alone, and GLP-1RA has been viewed as a ‘miracle drug’ by many of these people, who have been suffering from obesity for years without any available effective treatment options. Studies into other possible benefits of GLP-1RA drug usage began after these side effects, and they led to scientists announcing that it can boost cardiovascular health, protect the kidneys, reduce obesity-specific cancer, improve sleep apnea, and much more. In addition, humans are not the only ones benefiting from GLP-1. The term “Cat Ozempic” has gained traction recently, as a trial known as MEOW-1 aims to study the effects of GLP-1 in pets to treat obesity. 

Potential Drawbacks and Risks

While the new uses of GLP-1RA drugs are very positive and exciting, the explosive growth in usage has led to worldwide shortages, as greater numbers of people use the widely advertised GLP-1RA drugs for uses beyond their intended ones, preventing those who need them the most from receiving them. Additionally, concerns about unapproved ingredients, deceptive marketing practices, and concerning side effects have all contributed to some calls to slow down the pace of usage and development of GLP-1RA based products. The FDA and regulatory agencies have not yet caught up to the pace that companies are moving at with GLP-1RA based drugs, causing concern for some across the industry.

The future of GLP-1RA medicine

GLP-1RA medicine has scientists and the general public excited about its future uses. Researchers have hinted that it could treat depression, addiction, slow cognitive decline, and much more. Major pharmaceutical companies have allocated millions of dollars to new research and development of GLP-1RA and similar peptides to find new uses and improve existing treatments. While all of this is extremely exciting, and it is undoubtedly a major recent scientific advancement, there have been some warning calls that are often silenced by the large amount of public interest in these drugs. Reports from users of GLP-1RA drugs have described a range of side effects, from mild to severe. These reports have been validated by researchers, confirming a direct link between the reported effects and the GLP-1RA-derived drug. These could have some serious implications for potential future uses of GLP-1RA drugs, and they serve as a reminder of the need for caution and thorough evaluation as these medications are considered for broader applications. While this may sound detrimental to the hopes and future of GLP-1RA drugs, research is actively investigating these side effects to improve our understanding of their causes. Despite these challenges, GLP-1RA drugs hold immense promise, and continued innovations that involve GLP may unlock significant opportunities for future medical treatments.